The physiological actions of epinephrine and norepinephrine are mediated via the activation of the following three distinct classes of G protein-coupled receptors (GPCR) 1 : ␣ 1 -, ␣ 2 -, and ␤-adrenergic receptors. Each class of adrenergic receptor (AR) is comprised of three closely related subtypes as follows: ␣ 1A -, ␣ 1B -, and ␣ 1D AR, which couple primarily to G q to stimulate phospholipase activity; ␣ 2A -, ␣ 2B -, and ␣ 2C AR, which couple primarily to G i to inhibit adenylyl cyclase activity; and ␤ 1 -, ␤ 2 -, and ␤ 3 AR, which couple primarily to G s to stimulate adenylyl cyclase activity (1). The adrenergic receptor subtypes are differentially distributed across various tissues, and tissue responses to epinephrine and norepinephrine are believed to be dependent upon the relative ratios of the various adrenergic receptors they express.
These data reveal an interaction between ␤ 1 AR and ␣ 2A AR that is regulated by glycosylation and that may play a key role in cross-talk and mutual regulation between these receptors.
The physiological actions of epinephrine and norepinephrine are mediated via the activation of the following three distinct classes of G protein-coupled receptors (GPCR) 1 : ␣ 1 -, ␣ 2 -, and ␤-adrenergic receptors. Each class of adrenergic receptor (AR) is comprised of three closely related subtypes as follows: ␣ 1A -, ␣ 1B -, and ␣ 1D AR, which couple primarily to G q to stimulate phospholipase activity; ␣ 2A -, ␣ 2B -, and ␣ 2C AR, which couple primarily to G i to inhibit adenylyl cyclase activity; and ␤ 1 -, ␤ 2 -, and ␤ 3 AR, which couple primarily to G s to stimulate adenylyl cyclase activity (1) . The adrenergic receptor subtypes are differentially distributed across various tissues, and tissue responses to epinephrine and norepinephrine are believed to be dependent upon the relative ratios of the various adrenergic receptors they express.
Because ␤-and ␣ 2 -adrenergic receptors couple to G proteins with opposing actions on adenylyl cyclase activity, the two receptors might be expected to purely antagonize each other's signaling when they are co-stimulated in the same cell. However, it has been shown that ␣ 2 AR co-stimulation can in some cases paradoxically sensitize ␤-adrenergic signaling in brain tissue (2) (3) (4) . Moreover, the pharmacological properties of ␤ARs in brain tissue are known to be regulated by ␣ 2 ARs (5, 6), and reciprocally the pharmacological properties of ␣ 2 ARs in brain tissue are known to regulated by ␤ARs (7, 8) . These examples of cross-talk and mutual regulation between ␤-and ␣ 2 -adrenergic receptors have been well known for more than 20 years, but the underlying molecular mechanisms remain unclear.
GPCRs have traditionally been thought to exist as monomers, but recent studies (9) have revealed that they can exist in the plasma membrane as both homodimers and heterodimers. At present, a key question in this field is: how widespread is the phenomenon of receptor heterodimerization? The most clearcut case of the importance of GPCR heterodimerization comes from the GABA B receptor, a pharmacologically defined entity that is now known to be comprised of two distinct GPCRs, GABA B R1 and GABA B R2 (10) . Because GABA B R1 and GAB-A B R2 are not functional when expressed by themselves, they represent a clear example of the physiological importance of receptor heterodimerization. Although other heptahelical receptors may not absolutely require heterodimerization to be functional in the same way that the GABA B receptor does, heterodimerization of other receptors may underlie some phenomena that are major question marks in our present understanding of neurotransmitter and hormone receptors, such as unexplained forms of cross-talk between different receptor subtypes.
We wondered if the previously reported cross-talk between ␤ARs and ␣ 2 ARs in brain tissue might be due in part to a physical association between these two receptor types. Many early studies (11) (12) (13) of GPCR dimerization focused on the ␤ 2 AR. We have found recently (14) that the ␤ 1 AR also exhibits robust homodimerization in cells. Furthermore, it has been shown recently (15) that ␤ 1 AR and ␤ 2 AR can heterodimerize in a functionally important manner. ␤ 1 AR is the most abundantly expressed ␤AR in brain (16, 17) , a tissue where ␣ 2 ARs are found at particularly high levels (18) . The most widely expressed ␣ 2 AR subtype, ␣ 2A AR, is known to be localized both pre-and post-synaptically in a number of brain regions (18) , where its pattern of expression overlaps significantly with that of the ␤ 1 AR (17) . Based on the previously reported functional interactions between ␣ 2 ARs and ␤ARs, as well as the overlapping distribution patterns of ␣ 2A AR and ␤ 1 AR, we examined the possibility that ␤ 1 AR might be able to heterodimerize with ␣ 2A AR. Our findings reveal that ␤ 1 AR and ␣ 2A AR robustly associate in cells and that ␣ 2A AR can regulate ␤ 1 AR internalization and ligand binding.
MATERIALS AND METHODS
Plasmids-FLAG-␤ 1 AR was kindly provided by Robert J. Lefkowitz (Duke University). HA-␣ 2A AR was kindly provided by Lee Limbird (Vanderbilt University Medical Center). HA-␤ 1 AR was kindly provided by Hitoshi Kurose (University of Tokyo). The N15A mutant ␤ 1 AR was prepared via PCR amplification from the native human ␤ 1 AR cDNA using a mutant sequence oligonucleotide (CTG GGC GCC TCC GAG CCC GGT GCC CTG TCG TCG GCC GCA CCG CTC). The N10A/N14A mutant ␣ 2A AR was also prepared via PCR amplification from the wildtype construct in a two-step process, first using a mutant sequence oligonucleotide (CC CTG CAG CCG GAA GCG GGC GCC GCG AGC TGG AAT GGG ACA GAG G) to make the N10A mutation, and second using a second oligonucleotide (GCG GGC GCC GCG AGC TGG GCT GGG ACA GAG GCG CCG GGG GGC) to make the N14A mutation using the N10A mutant construct as a template. The point mutations were confirmed by ABI sequencing.
Cell Culture and Transfection-All tissue culture media and related reagents were purchased from Invitrogen. HEK-293 cells were maintained in complete medium (Dulbecco's modified Eagle's medium plus 10% fetal bovine serum and 1% penicillin/streptomycin) in a 37°C, 5% CO 2 incubator. For heterologous expression of receptors, 2 g of DNA was mixed with LipofectAMINE (15 l) and Plus reagent (20 l) (from Invitrogen) and added to 5 ml of serum-free medium in 10-cm tissue cultures plates containing cells at ϳ50 -80% confluency. Following a 4-h incubation, the medium was removed, and 10 ml of fresh complete medium was added. After another 12-16 h, the medium was changed again, and the cells were harvested 24 h later.
Western Blotting-Samples (5 g per lane) were run on 4 -20% SDS-PAGE gels (Invitrogen) for 1 h at 150 V and then transferred to nitrocellulose. The blots were blocked in "blot buffer" (2% non-fat dry milk, 0.1% Tween 20, 50 mM NaCl, 10 mM Hepes, pH 7.4) for at least 30 min and then incubated with primary antibody in blot buffer for 1 h at room temperature. The primary antibodies utilized were either a 12CA5 monoclonal anti-HA antibody (Roche Molecular Biochemicals) or an M2 monoclonal anti-FLAG antibody (Sigma). The blots were then washed three times with 10 ml of blot buffer and incubated for 1 h at room temperature with a horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences) in blot buffer. Finally, the blots were washed three more times with 10 ml of blot buffer and visualized via enzyme-linked chemiluminescence using the ECL kit from Amersham Biosciences.
Immunoprecipitation-Cells were harvested and lysed in 500 l of ice-cold lysis buffer (10 mM Hepes, 50 mM NaCl, 0.5% Triton X-100, 5 mM EDTA, and the protease inhibitor mixture from Roche Molecular Biochemicals). The lysate was solubilized via end-over-end rotation at 4°C for 30 min and clarified via centrifugation at 14,000 rpm for 15 min. A small fraction of the supernatant was taken at this point and incubated with SDS-PAGE sample buffer in order to examine expression of proteins in the whole cell extract. The remaining supernatant was incubated with 30 l of beads covalently linked to anti-FLAG antibodies (Sigma) for 2 h with end-over-end rotation at 4°C. After five washes with 1.0 ml of lysis buffer, the immunoprecipitated proteins were eluted from the beads with 1ϫ SDS-PAGE sample buffer, resolved by SDS-PAGE, and subjected to Western blot analyses.
Enzymatic Deglycosylation-For enzymatic deglycosylation of receptors, immunoprecipitates were separated from beads by boiling for 10 min in a denaturing buffer (0.5% SDS containing 1% ␤-mercaptoethanol). After cooling, Nonidet P-40 was added to the supernatants to a final concentration of 1%, and Na 2 HPO 4 /NaH 2 PO 4 buffer (pH 7.5) was added to lysates to a final concentration of 50 mM. N-glycosidase F (1,500 units; New England Biolabs) was added to a 30-l reaction volume, and the sample was incubated for 1 h at 37°C.
Cyclic AMP Assay-Intracellular cAMP was measured by using a non-acetylation cAMP enzyme immunoassay kit (Amersham Biosciences). Briefly, cultured cells were transfected with either FLAG-␤ 1 AR alone or FLAG-␤ 1 AR/HA-␣ 2A AR in combination. After 24 h, cells were split into 6-well culture dishes with fresh medium. After another 48 h, cells were treated with varying concentrations of isoproterenol for 10 min and harvested with cell harvest buffer (50 mM Tris, pH 7.4, 250 M Ro 20-1724 (Tocris, Ellisville, NJ), 5 mM MgCl 2 , 1 mM ATP, and 1 M GTP). Cell lysates were sonicated, transferred to a 96-well assay plate coated with anti-rabbit IgG, and incubated with an anti-cAMP antibody at 4°C for 2 h along with a series of cAMP standards. A cAMPperoxidase conjugate was then added to the microtiter plate and incubated at 4°C for 1 h. The plate was then washed four times with 400 l of wash buffer, and the wells were incubated with 150 l of enzyme substrate at room temperature for 1 h. When the samples were within the linear range of the standards, the reaction was stopped by adding 100 l of 1.0 M sulfuric acid. Absorbance was determined in a plate reader at 450 nm, and cAMP levels were determined using standard curves.
Surface Expression Assay-Transfected cells were split into 35-mm dishes, grown for 48 h, and then incubated in the absence and presence of agonist for 10 min. The cells were then rinsed in PBS and fixed with 4% paraformaldehyde in PBS for 30 min and then rinsed three times in PBS and blocked with blocking buffer (2% non-fat dry milk in PBS, pH 7.4) for 30 min. The fixed cells were then incubated with primary antibody in blocking buffer for 1 h at room temperature. The dishes were subsequently washed three times with 2 ml of block buffer and incubated for 1 h at room temperature with horseradish peroxidaseconjugated secondary antibody (Amersham Biosciences) in blocking buffer. Finally, the dishes were washed three times with 2 ml of blocking buffer and one time with 2 ml of PBS and then incubated with 2 ml of ECL reagent (Pierce) for exactly 15 s. The luminescence, which corresponds to the amount of receptor on the cell surface, was determined by placing the plate inside a TD 20/20 luminometer (Turner Designs).
Ligand Binding Assays-For preparation of membranes to be used in ligand binding assays, transfected cells grown on 100-mm dishes were rinsed twice with 10 ml of PBS and then scraped into 1 ml of ice-cold binding buffer (10 Incubations were terminated via filtration through GF/C filter paper using a Brandel cell harvester. Filters were rapidly washed three times with ice-cold wash buffer (10 mM Hepes), and radioactive ligand retained by the filters was quantified via liquid scintillation counting. The fitting of curves for one site versus two sites was performed using Prism software (GraphPad, San Diego, CA). Goodness of fit was quantified using F tests, comparing sum-of-squares values for the one-site versus two-site fits.
Immunofluorescence Microscopy-HEK-293 cells were transiently transfected with pcDNA3/FLAG-␤ 1 AR and pcDNA3/HA-␣ 2A AR. Forty eight hours after transfection, cells were washed three times with Dulbecco's PBS and then incubated for 10 min at 37°C in the absence or presence of 10 M isoproterenol or 10 M UK 14,304 (Sigma). Following this incubation, cells were fixed in 4% paraformaldehyde in PBS for 30 min at room temperature. To visualize the subcellular localization of ␤ 1 AR and ␣ 2A AR, cells were blocked and permeabilized with a buffer containing 2% bovine serum albumin and 0.04% saponin in PBS ("saponin buffer") for 30 min at room temperature. The cells were then incubated with anti-␤ 1 AR polyclonal antibody (Santa Cruz Biotechnology) at 1:500 dilution and anti-HA monoclonal antibody (12CA5; Roche Molecular Biochemicals) at 1:1000 dilution for 1 h at room temperature. After three washes (1 min) with saponin buffer, the cells were incubated with a rhodamine red-conjugated anti-rabbit IgG at 1:200 dilution and FITC-conjugated anti-mouse IgG at 1:200 dilution (Jackson ImmunoResearch Laboratories) for 1 h at room temperature. After three washes (1 min) with saponin buffer and one wash with PBS, coverslips were mounted, and rhodamine red-labeled ␤ 1 AR and FITC-labeled ␣ 2A AR were visualized with a Zeiss LSM-410 laser confocal microscope. Multiple control experiments, utilizing either transfected cells in the absence of primary antibody or untransfected cells in the presence of primary antibody, revealed a very low level of background staining, indicating that the primary antibody-dependent immunostaining observed in the transfected cells was specific. and 120 kDa. The higher order bands presumably represent receptor complexes resistant to separation by SDS-PAGE, as is commonly observed for many GPCRs (9) . When the FLAGtagged ␤ARs were immunoprecipitated with an anti-FLAG antibody, the co-transfected HA-␣ 2A AR was robustly co-immunoprecipitated. All of the bands of HA-␣ 2A AR immunoreactivity were evident in FLAG-␤AR immunoprecipitates. Somewhat more co-immunoprecipitation was observed with ␤ 1 AR than with ␤ 2 AR, and thus further experiments in this area focused on the ␤ 1 AR/␣ 2A AR interaction. No changes in the extent of co-immunoprecipitation were observed when cells were stimulated before harvesting with various adrenergic receptor agonists (data not shown). In related control experiments, HA-␣ 2A AR and FLAG-␤ 1 AR were transfected separately into different plates of cells, which were harvested, prepared as detergent-solubilized lysates, and then mixed together. Immunoprecipitation of FLAG-␤ 1 AR in these experiments did not yield any detectable co-immunoprecipitation of HA-␣ 2A AR (data not shown), revealing that the two receptors need to be expressed in the same cell in order to physically associate.
RESULTS

Co-immunoprecipitation of ␣
Co-internalization of ␣ 2A -and ␤ 1 -Adrenergic Receptors-As a second method of assessing the physical association between ␣ 2A AR and ␤ 1 AR, we expressed the two receptors in cells and studied their co-internalization. Agonist stimulation of many GPCRs induces significant internalization from the cell surface, and this process is known to be important in the desensitization and resensitization of GPCR responses (19) . HA-␣ 2A AR and FLAG-␤ 1 AR were expressed either separately or together in HEK-293 cells and then stimulated with one of three agonist conditions: the ␤AR agonist isoproterenol alone ("Iso"), the ␣ 2 AR agonist UK 14,034 alone ("UK"), or Iso ϩ UK together. When endocytosis of ␣ 2A AR was examined via a quantitative luminometer-based assay ( Fig. 2A) , no significant internalization was observed in response to Iso under any condition, whereas internalization in response to UK was ϳ15% whether Iso was co-applied or not. When endocytosis of ␤ 1 AR was examined (Fig. 2B) , ϳ25-30% receptor internalization was observed in response to Iso. The extent of internalization was not significantly different for ␤ 1 AR expressed alone as compared with ␤ 1 AR expressed in the presence of ␣ 2A AR. In response to UK, no significant internalization was observed for ␤ 1 AR expressed alone, which is the expected result because UK does not activate ␤ 1 AR. Strikingly, however, ␤ 1 AR coexpressed with ␣ 2A AR exhibited ϳ15% internalization in response to UK stimulation. These data indicate that stimulation of ␣ 2A AR can cause co-internalization of ␤ 1 AR.
The internalization of ␣ 2A AR and ␤ 1 AR was also studied via immunofluorescence confocal microscopy. In cells co-transfected with HA-␣ 2A AR and FLAG-␤ 1 AR, immunostaining for both receptors was concentrated into a smooth rim along the edge of the cells, which presumably corresponds to receptor and ␤ 1 AR (B) was examined using a luminometer-based assay following 10-min stimulations with the ␤-adrenergic agonist isoproterenol (Iso; 10 m), the ␣ 2 -adrenergic agonist UK 14,304 (UK; 10 M), or a combination of the two agonists together. As shown in A, ␣ 2A AR exhibited ϳ15% internalization in response to UK stimulation but no significant internalization in response to isoproterenol under any condition. Conversely, as shown in B, ␤ 1 AR exhibited ϳ25-30% internalization in response to isoproterenol but also exhibited ϳ15% internalization in response to stimulation with UK. This effect was only observed, however, when ␣ 2A AR was coexpressed (** indicates significantly different from ␤ 1 AR alone, p Ͻ 0.01). These data suggest that ␤ 1 AR can co-internalize with agonist-activated ␣ 2A AR. The bars and error bars represent the means Ϯ S.E. for 4 -5 independent experiments for each condition, with each experiment being performed in triplicate. localization in the plasma membrane of the cells (Fig. 3, A-C) . Stimulation with Iso resulted in the development of significant intracellular immunostaining for FLAG-␤ 1 AR (Fig. 3D) but had no apparent effect on the pattern of immunostaining for HA-␣ 2A AR (Fig. 3E) . In contrast, stimulation with UK resulted in mobilization of both HA-␣ 2A AR and FLAG-␤ 1 AR inside the cell (Fig. 3, G and H) , where the two receptors exhibited significant co-localization (Fig. 3I) . These data are consistent with the findings obtained using the luminometer-based assay (Fig.  2) Fig. 4 ; Table I ). In contrast, curves for displacement of [ 3 H]DHA binding to membranes expressing ␤ 1 AR/␣ 2A AR were in most cases fit significantly better by two-site analyses rather than one-site analyses. The appearance of a significant low affinity component for the displacement of [ 3 H]DHA by metoprolol, labetalol, bisoprolol, dobutamine, and isoproterenol suggests that these ligands bind with substantially lower affinity to ␤ 1 AR/␣ 2A AR heterodimers than to ␤ 1 AR alone. On the other hand, norepinephrine, an endogenous agonist for both ␣-and ␤-adrenergic receptors, exhibited slightly enhanced affinity for binding to the ␤ 1 AR in the presence of ␣ 2A AR coexpression as compared with ␤ 1 AR expressed alone, whereas epinephrine, which is also an endogenous agonist for both receptors, exhibited no significant change in its apparent affinity for ␤ 1 AR alone versus ␤ 1 AR/␣ 2A AR. In control experiments, membranes derived from cells expressing ␤ 1 AR alone and ␣ 2A AR alone were mixed together, as in the control co-immunoprecipitation experiments described above. In these mixing experiments, no changes in the ligand binding properties of ␤ 1 AR were observed for any of the ligands examined (data not shown), suggesting that ␤ 1 AR and ␣ 2A AR must be expressed in the same cell for the modulation of ␤ 1 AR pharmacological properties to occur. Furthermore, the effects of ␣ 2A AR coexpression on ␤ 1 AR ligand binding properties were not blocked by treatment of the cells with pertussis toxin prior to harvesting (data not shown), suggesting that these effects are not due to activation of G i /G o -dependent intracellular signaling pathways by the coexpressed ␣ 2A AR. In related experiments, the binding of various ␣ 2 AR-selective ligands to membranes expressing ␣ 2A AR alone versus ␤ 1 AR/ ␣ 2A AR was examined. No differences in the binding properties of the ␣ 2 AR-selective agonist UK 14,034, the ␣ 2 AR-selective partial agonist clonidine, or the ␣ 2 AR-selective partial agonist guanfacine were observed (Table II Table I for a summary of other ligands examined in these experiments). Notably, the curve for bisoprolol inhibition of [ 3 H]DHA binding was well fit by assuming a single binding site in the case of ␤ 1 AR alone but was a significantly better fit by a two-site analysis in the case of the ␤ 1 AR/␣ 2A AR co-transfected samples. The points and error bars shown are the means Ϯ S.E. for 4 independent determinations each.
signaling. We utilized a transfection-based approach to study ␤ 1 AR stimulation of cAMP production in the absence and presence of ␣ 2A AR coexpression in HEK-293 cells. These studies revealed that isoproterenol was significantly less potent at stimulating cAMP production when ␤ 1 AR was expressed in the presence of ␣ 2A AR than when ␤ 1 AR was expressed alone (Fig. 5) . The maximal extent of cAMP production, however, was comparable in both cases, and the expression level of ␤ 1 AR was unaltered by coexpression of ␣ 2A AR. Moreover, the effect of ␣ 2A AR coexpression on isoproterenol-induced cAMP production was not attributable to constitutive coupling of ␣ 2A AR to G i , because the effect was not blocked by pertussis toxin treatment (data not shown). These data reveal that isoproterenol has a higher potency at ␤ 1 AR expressed alone versus ␤ 1 AR coexpressed with ␣ 2A AR. These findings are consistent with the ligand binding data presented in Table I , which indicate that coexpression with ␣ 2A AR results in reduced ␤ 1 AR affinity for isoproterenol and other ␤AR-selective ligands.
Regulation of ␣ 2A -AR/␤ 1 AR Heterodimerization by Receptor
Glycosylation-Glycosylation of G protein-coupled receptors can have variable effects on receptor trafficking and signaling (20) . The ␤ 1 AR contains one consensus site for N-linked glycosylation on its extracellular amino terminus (Asn-15). We mutated this site to alanine, creating a mutant receptor (N15A) that exhibited a significant decrease in apparent size on SDS-PAGE (Fig. 6A ). Enzymatic deglycosylation with N-glycosidase F also decreased the apparent size of the wild-type ␤ 1 AR on SDS-PAGE but had no effect on the apparent size of the N15A mutant receptor suggesting that Asn-15 is the sole site of ␤ 1 AR N-linked glycosylation (21) . We examined the capacity of the N15A mutant receptor for heterodimerization with the ␣ 2A AR. HA-␣ 2A AR was coexpressed with either FLAG-␤ 1 AR wild-type or FLAG-␤ 1 AR N15A, which exhibited equivalent levels of total One-site and two-site fits of each data set were performed as described under "Materials and Methods." The inhibition curves for ␤ 1 AR/␣ 2A AR were significantly better fit by two-site fits rather than one-site fits for all ligands except for propranolol, norepinephrine, and epinephrine, whereas the inhibition curves for ␤ 1 AR alone were not significantly better fit in any case by two-site fits relative to one-site fits. Hence, two K i values (K H for the high affinity component and K L for the low affinity component) are provided for binding to ␤ 1 AR/␣ 2A AR for most of the ligands, whereas only a single K i value is provided for binding to ␤ 1 AR expressed alone. Note that for all of the two-site fits, the K H value for binding to ␤ 1 AR/␣ 2A AR is similar to the single K i value for binding to ␣ 2A AR alone, suggesting that the majority of binding sites in the membranes expressing ␤ 1 AR/␣ 2A AR possess binding properties similar to the binding sites in membranes expressing ␤ 1 AR alone. However, membranes expressing ␤ 1 AR/␣ 2A AR also exhibit, in most cases, a small low affinity component (K L ), which was estimated between 10 and 25% of total binding sites in all cases, as shown in the right-hand column. The data for these inhibition curves were derived from 3 to 5 independent determinations for each ligand. to lysed membranes was also studied in the presence of increasing concentrations of several other ␣-adrenergic receptor ligands. The estimated K i values (in nM) are shown for each ligand. The levels of significance of differences in ligand binding to ␣ 2A AR/␤ 1 AR relative to ␣ 2A AR alone were assessed via t tests, and no significant differences were found between any of the matched sets. Moreover, one-site versus two-site fits were performed as described under "Materials and Methods" and in no cases were two-site fits significantly better than one-site fits. Thus, ␣ 2A AR ligand binding properties showed no obvious differences when ␣ 2A AR was examined in the absence and presence of ␤ 1 AR coexpression. The data for these inhibition curves were derived from three independent determinations for each ligand. cellular expression as shown in Fig. 6A . The FLAG-tagged ␤ 1 ARs were immunoprecipitated with an anti-FLAG antibody, and the amount of co-immunoprecipitated HA-␣ 2A AR was examined via Western blot (Fig. 6B) and quantified (as shown in Fig. 6C ). Strikingly, ␣ 2A AR was co-immunoprecipitated much more efficiently with the N15A mutant ␤ 1 AR than with the wild-type ␤ 1 AR. These data reveal that blockade of ␤ 1 AR glycosylation enhances ␤ 1 AR heterodimerization with ␣ 2A AR.
Because ␣ 2A AR/␤ 1 AR heterodimerization was more efficient for the N15A mutant, we examined whether or not ␣ 2A AR might exert a more robust regulation of N15A-␤ 1 AR relative to wild-type ␤ 1 AR. However, we found that agonist-promoted ␤ 1 AR internalization following a 10-min stimulation with UK 14,304 was not significantly different for wild-type ␤ 1 AR versus the N15A mutant (wild type ϭ 16.8 Ϯ 3.5%; N15A ϭ 18.0 Ϯ 4.4% in matched plates examined side-by-side; n ϭ 3). Similarly, the changes in ligand binding properties induced by coexpression with ␣ 2A AR were comparable for the wild-type ␤ 1 AR and the N15A mutant (data not shown). Thus, although blockade of ␤ 1 AR glycosylation results in a clear enhancement of ␣ 2A AR/␤ 1 AR heterodimerization, it may not lead to an enhancement in heterodimerization of functional receptors on the cell surface. This observation may be related to the fact that the N15A mutant ␤ 1 AR is deficient in its ability to traffic to the cell surface relative to the wild-type receptor (21) .
The ␣ 2A AR is also known to be glycosylated on its amino terminus, on residues Asn-10 and Asn-14 (22) . We therefore prepared a mutant version of the ␣ 2A AR (N10A/N14A) that cannot be glycosylated. Transfection of this mutant construct into HEK-293 cells resulted in the expression of receptors with significantly decreased apparent size on SDS-PAGE gels relative to wild-type ␣ 2A AR (Fig. 6D) , as reported previously (22) . The heterodimerization of the HA-tagged N10A/N14A mutant with wild-type FLAG-␤ 1 AR was assessed in side-by-side experiments in comparison to the heterodimerization of wild-type ␣ 2A AR with wild-type FLAG-␤ 1 AR (Fig. 6E) . The N10A/N14A mutant ␣ 2A AR exhibited an ϳ3-fold enhancement over wildtype ␣ 2A AR in heterodimerization with ␤ 1 AR (Fig. 6F ). Taken together with the experiments described above examining the N15A ␤ 1 AR, these findings indicate that blockade of glycosylation of both ␣ 2A AR and ␤ 1 AR results in enhanced ␣ 2A AR/␤ 1 AR heterodimerization.
DISCUSSION
Our findings reveal a functionally important heterodimerization between ␣ 2A -and ␤ 1 -adrenergic receptors. The evidence for the physical association of these two receptor subtypes is derived from both co-immunoprecipitation and co-internalization assays. The co-internalization experiments not only represent evidence for the physical association of the two receptors, they also represent a specific mechanism by which ␣ 2A AR stimulation may influence ␤ 1 AR function. Although ␣ 2 ARs and ␤ARs couple primarily to G proteins with opposing cellular effects on cAMP production, it is known that agonist activation of ␣ 2 ARs can in some cases paradoxically sensitize ␤AR signaling in brain tissue (2) (3) (4) . Because internalization of GPCRs is known to play a key role in promoting GPCR resensitization (19) , our observation that ␣ 2A AR stimulation can promote ␤ 1 AR internalization provides a specific molecular mechanism that could potentially account for the previously reported ability of ␣ 2 AR stimulation to sensitize ␤AR-mediated responses in native tissues.
Coexpression of ␣ 2A AR and ␤ 1 AR in our studies not only allowed for ␣ 2A AR regulation of ␤ 1 AR internalization, it also resulted in altered ␤ 1 AR pharmacological properties. We found that the curves for displacement of [ 3 H]DHA binding to membranes expressing ␤ 1 AR alone were fit well by one-site analyses for all ligands examined. Whereas it is true that analyses of agonist binding to ␤-adrenergic receptors often require resolution into two sites, which correspond to G protein-coupled (high affinity) versus uncoupled (low affinity) states (23), our analyses of agonist binding to ␤ 1 AR alone were fit well by assuming a single site. This is probably due to the fact that the transfected ␤ 1 AR was expressed in our cells at much higher levels than the endogenous G proteins, meaning that the G proteincoupled (high affinity) component of agonist binding to the receptors in our assays represented only a tiny and unresolvable component of the inhibition curves. In any case, coexpression of ␤ 1 AR with ␣ 2A AR resulted in the appearance of a significant low affinity component of binding for many of the ␤AR-selective ligands. Our interpretation of these data is that a proportion of the ␤ 1 AR in the cells assembled with ␣ 2A AR to form heterodimers that exhibited unaltered affinity for some ligands (such as DHA and propranolol), substantially reduced affinity for other ligands (such as metoprolol, labetalol, bisoprolol, isoproterenol and dobutamine), and slightly increased affinity for yet other ligands (such as the endogenous agonist norepinephrine). Many of the ligands examined share significant structural similarity, and it is therefore uncertain why the binding properties of the various ligands should be differentially altered by ␤ 1 AR coexpression with ␣ 2A AR. Moreover, the affinity constant values derived for the low affinity component of binding in these studies must be considered as rough estimates, because it is difficult to derive accurate affinity constant estimates from curves where the size of the low affinity component (10 -25%) represents such a small minority of the total population of binding sites.
A question of interest is why coexpression of ␤ 1 AR with ␣ 2A AR should result in ligand binding curves that are best fit by two sites, rather than simply resulting in a single population of novel binding sites as might be expected if every ␤ 1 AR were to heterodimerize with an ␣ 2A AR to form receptors with novel pharmacological properties. The most likely explanation for the observed mixed population of binding sites is that, regardless of how efficiently ␣ 2A AR heterodimerizes with ␤ 1 AR, it is unlikely that all ␤ 1 AR in a given cell will form heteromeric complexes with coexpressed ␣ 2A AR. A large proportion of cellular ␤ 1 -adrenergic receptors are likely to exist either as monomers or homodimers, with only a fraction of the total ␤ 1 AR population assembling with other receptors such as ␣ 2A AR. Thus, studies examining the binding of ligands to co-transfected ␣ 2A AR/␤ 1 AR are almost certainly studying mixed populations of receptors, complicating attempts to estimate the true changes in ␤ 1 AR pharmacological properties induced by heterodimerization with ␣ 2A AR. This is a general problem shared by all studies examining pharmacological changes induced by heterodimerization of GPCRs.
Over the past several years, heterodimerization of a number of different types of GPCRs has been reported. Examples where heterodimerization is required for the formation of functional receptors include the GABA receptors GABA B R1 and GAB-A B R2 (10) and the taste receptor combinations T1R1/T1R3 and T1R2/T1R3, which have been reported to form receptors for umami and sweet stimuli, respectively (24 -26) . Examples where heterodimerization allows for cross-regulation between receptors but is not required for receptor function include the following: ␤ 1 -and ␤ 2 -adrenergic receptors (15); ␦ and opioid receptors (27) ; ␦ and opioid receptors (28, 29) ; ␦ opioid and ␤ 2 -adrenergic receptors (30, 31) ; muscarinic acetylcholine M2 and M3 receptors (32); angiotensin AT1 and bradykinin B2 receptors (33); dopamine D1 and adenosine A1 receptors (34); dopamine D2 and somatostatin SSTR5 receptors (35); dopamine D2 and adenosine A2 receptors (36); mGluR1 glutamate and A1 adenosine receptors (37); SSTR1 and SSTR5 somatostatin receptors (38); SSTR2A and SSTR3 somatostatin receptors (39) ; and opioid and SSTR2A somatostatin receptors (40) . Many of these receptor/receptor interactions have been found to result in altered pharmacological properties for one or both receptors (27-29, 32, 35, 38, 39) , similar to what we have found for the ␣ 2A AR/␤ 1 AR interaction. Additionally, several of the previously reported (30, 36, 40) receptor-receptor interactions have been found to facilitate receptor co-internalization, similar to our observation that stimulation of ␣ 2A AR can lead to co-internalization of ␤ 1 AR.
In both the luminometer-based surface expression assays and the immunofluorescence microscopy experiments performed on ␣ 2A AR/␤ 1 AR co-transfected cells, we observed that ␣ 2A AR stimulation resulted in internalization of both ␣ 2A AR and ␤ 1 AR, whereas stimulation of ␤ 1 AR resulted in internalization of only ␤ 1 AR. The reason for this difference is not clear.
It may be case that the ␣ 2A AR/␤ 1 AR heterodimer has internalization properties that are distinct from either of the two individual receptors. Alternatively, ␣ 2A AR/␤ 1 AR heterodimerization may be impaired by ␤-adrenergic agonist stimulation, allowing ␤ 1 AR to temporarily internalize in the absence of ␣ 2A AR co-internalization. Our co-immunoprecipitation studies, however, did not reveal any consistent effects of agonist stimulation on the amount of HA-␣ 2A AR co-immunoprecipitated with FLAG-␤ 1 AR. It is uncertain, however, whether or not this technique is sensitive enough to detect changes in ␣ 2A AR/␤ 1 AR co-immunoprecipitation in the range of 10 -20%, as might be expected if receptor internalization were correlated with a temporary release from heterodimerization. One thing that is interesting to note is the similarity between our findings for the effects of ␣ 2A AR/␤ 1 AR heterodimerization on receptor ligand binding properties versus internalization; we found that assembly with ␣ 2A AR influenced ␤ 1 AR pharmacological properties, whereas conversely assembly with ␣ 2A AR did not result in any evident change in the ligand binding properties of ␣ 2A AR. Similarly, we found that ␣ 2A AR stimulation led to ␤ 1 AR internalization, but conversely ␤ 1 AR stimulation did not lead to any evident internalization of ␣ 2A AR. Thus, for both ligand binding and internalization, ␣ 2A AR was able to influence ␤ 1 AR, but ␤ 1 AR was not able to influence ␣ 2A AR.
If ␤ 1 -adrenergic receptors can form ␤ 1 AR/␤ 1 AR homodimers (14) , ␤ 1 AR/␤ 2 AR heterodimers (15) , and ␤ 1 AR/␣ 2A AR heterodimers, as the present data reveal, it is a point of significant interest to understand the factors that regulate the proportion of cellular homodimers versus heterodimers. Studies on the dimerization of other GPCRs have provided evidence that agonist stimulation can regulate dimerization (9) . However, as mentioned above, our co-immunoprecipitation experiments did not reveal any consistent effects of agonist stimulation on ␣ 2A AR/␤ 1 AR heterodimerization. Association with cytoplasmic scaffold proteins is another factor that might potentially regulate heterodimer formation. The ␤ 1 -adrenergic receptor is known to associate with PSD-95/Discs-large/ZO-1 homology domain-containing scaffold proteins such as PSD-95 (14, 41, 42) and MAGI-2 (14) . However, we have not observed any significant effects of PSD-95 or MAGI-2 coexpression on the extent of either ␤ 1 AR/␤ 1 AR homodimerization (14) or ␣ 2A AR/ ␤ 1 AR heterodimerization (data not shown). The ␣ 2A -adrenergic receptor is known to associate with cytoplasmic proteins such as 14-3-3 (43) and spinophilin (44), but we have not examined the effects of these interactions on ␣ 2A AR/␤ 1 AR heterodimerization.
One additional way that receptor heterodimerization might be regulated is via post-translational receptor modifications. A post-translational modification common to many GPCRs is receptor glycosylation (20) . We have found that the ␤ 1 AR is N-glycosylated on a single residue, Asn-15, and that ␣ 2A AR/ ␤ 1 AR heterodimerization is markedly enhanced via mutation of Asn-15 to an amino acid that cannot be glycosylated. Moreover, we have also found that ␣ 2A AR/␤ 1 AR heterodimerization is enhanced by blocking glycosylation of the ␣ 2A AR. These data could indicate that lack of glycosylation alters the conformations of the ␣ 2A AR and ␤ 1 AR such that the efficiency of their heterodimerization is increased. Alternatively, it is possible that the enhanced heterodimerization of the N10A/N14A ␣ 2A AR and N15A ␤ 1 AR is the result of a more global alteration in the trafficking and processing of the mutant receptors. Interestingly, we have found previously (21) that ␤ 1 AR homodimerization is impaired for the ␤ 1 AR-N15A mutant relative to the wild-type receptor. Thus, our data indicate that blockade of glycosylation has differential effects on ␤ 1 AR homoversus heterodimerization. In any case, it is known that the glycosylation state of transmembrane receptors can vary significantly in different tissue types (45, 46) . The glycosylation state of the ␤ 1 AR in particular is known to be regulated via polymorphic variation (47) . Thus, the extent of ␣ 2A AR/␤ 1 AR heterodimerization may be regulated differentially between tissues and between individuals via differences in ␤ 1 AR glycosylation state.
In summary, we have found a physical association between ␣ 2A -and ␤ 1 -adrenergic receptors. This heterodimerization alters ␤ 1 AR pharmacological properties and facilitates cross-internalization of ␤ 1 AR following ␣ 2A AR agonist stimulation. Both ␣ 2A AR and ␤ 1 AR are abundantly expressed in the brain, and heterodimerization of these two receptors might therefore underlie previously reported functional cross-talk between endogenous ␣ 2 -and ␤-adrenergic receptors in brain tissue (2) (3) (4) (5) (6) (7) (8) . Therapeutic drugs acting on ␣ 2 ARs (such as clonidine) and ␤-adrenergic receptors (such as propranolol and metoprolol) are commonly utilized in the treatment of hypertension and are known to exhibit significant clinical interactions (48, 49) . The heterodimerization of ␣ 2A AR and ␤ 1 AR described here may help to provide new insights into both physiological cross-talk between ␣ 2 -and ␤-adrenergic receptors and clinical interactions between therapeutic drugs acting on these receptor subtypes.
